ORCID
0000-0002-1797-0447
Abstract
Multiple myeloma is commonly associated with advanced age. This study aims to investigate how multiple myeloma outcomes are affected by opioid use disorder (OUD) among hospitalized patients. We analyzed the National Inpatient Sample (NIS) for 2019 and 2020 for our retrospective cohort study. International Classification of Diseases Clinical Modification codes (ICD-10-CM) were utilized to identify the population of interest. Primary and secondary outcomes were studied using a multivariate regression model. Among the 38,735 patients hospitalized with multiple myeloma, 350 patients had the concurrent diagnosis of opioid use disorder. OUD patients were found to be at increased risk for major depressive disorder aOR[1] 2.57 (95% CI 1.39–4.755), p = 0.003; delirium aOR 3.48 (95% CI 1.066–11.38); p = 0.04; insomnia aOR 2.77 (95% CI 1.31–5.87); p= 0.008; and hypercalcemia aOR 2.71 (95% CI 1.31–5.63) p= 0.007. Total hospitalization charges decreased in patients with OUD, and no significant difference between the two groups in the length of hospital stay or mortality was noted. Among patients admitted with OUD, the rates of delirium, major depressive disorder, insomnia, and hypercalcemia were higher than those without any OUD without any significant difference in mortality.
[1]aOR: Adjusted Odds Ratio
Included in
Hematology Commons, Internal Medicine Commons, Oncology Commons
